Identification of benign from malignant small renal tumors: is there a possible role of T1 mapping?

鉴别良性与恶性小肾肿瘤:T1 映射是否可能发挥作用?

阅读:1

Abstract

PURPOSE: Differentiating benign from malignant small renal tumors (SRMs) can help to guide clinical decision-making. T1 mapping enables quantitative assessment of T1 relaxation time and may help to evaluate SRMs properties. This study aimed to investigate the possible utility of T1 mapping for identification of SRMs. METHODS: The data set used in this retrospective study, consisted of 104 patients with SRMs (≤ 4 cm). 78 malignant and 25 benign ones respectively. Calculated and compared the quantitative variables (including T1 mapping) between different renal tumors. The clinical features qualitative characteristics were subsequently documented. Finally, the logistic regression models were used to identify independent influencing factors. The diagnostic accuracy of independent influencing factors was represented with the area under the receiver operating characteristic curve (AUC). RESULTS: The pre-contrast T1 mapping (T1) and the ratio of T1 reduction in malignance were higher than those in benign SRMs, while post-contrast T1 mapping was lower (all P < 0.025). In multivariable logistic regression, the tumor necrosis (odds ratio (OR) = 20.636, P = 0.005) and T1 (OR = 2.982, P = 0.002) were independent predictors. For the identification of SRMs, the performance of the model achieving an AUC of 0.793 (95% CI 0.701-0.866) when combining two factors. CONCLUSION: Quantitative T1 mapping parameters may be a new potential biomarker for noninvasively distinguishing SRMs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。